In Vivo Xenograft Models for Preclinical Cancer Research

220 concepts209 papers7 proposals

In vitro cell cultures provide a highly controlled environment to observe molecular mechanisms, but they fail to capture the systemic complexity of a living organism. A drug that successfully halts proliferation on a plastic dish may fail in a patient due to poor pharmacokinetics, tissue-specific microenvironments, or systemic toxicity. To bridge this gap, researchers rely on in vivo xenograft models—transplanting foreign cancer cells or tissues into a living animal host.

In MicroRNA-218 Inhibits Cell Cycle Progression and Promotes Apoptosis in Colon Cancer by Downregulating BMI1 Polycomb Ring Finger Oncogene, Xinqi He et al. note that this approach provides a critical physiological bridge, allowing for the evaluation of molecular treatments within a complex biological environment. By moving from a petri dish to a living system, researchers can validate whether the growth inhibition observed in vitro truly translates to a whole-organism context, as shown in In Vitro and in Vivo Anticancer Effects of American Ginseng Berry: Exploring Representative Compounds by Jing-Tian Xie et al.

Bypassing the Immune Barrier

The primary biological challenge of xenografting human cells into another species is graft rejection: a host's immune system will naturally destroy foreign tissue. To circumvent this, researchers traditionally utilize immunodeficient animal models. For instance, severe combined immunodeficient (SCID) mice lack functional T and B cells, preventing them from rejecting human cells and enabling the unhindered expansion of human tumors, a mechanism leveraged in The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. by Edgar Selzer et al.

Similarly, athymic nude mice lack a thymus and cannot produce T cells, making them highly receptive hosts for evaluating oncogenic progression, as detailed in Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma by Kawuli Jumai et al. To better model human diseases in higher organisms, recent advancements have even extended this approach to non-human primates; Xiao Zheng et al. developed Generation of inactivated IL2RG and RAG1 monkeys with severe combined immunodeficiency using base editing, utilizing base editing to create a severely compromised immune environment capable of supporting human cancer cell engraftment for preclinical drug testing.

Spatial Context: Subcutaneous vs. Orthotopic Modeling

Where a tumor is placed inside the host drastically alters the insights a model can provide. The most straightforward approach is the subcutaneous xenograft model, where cancer cells are injected just beneath the skin, as described in Inhibition of SATB1 by shRNA Suppresses the Proliferation of Cutaneous Malignant Melanoma by Fang Cheng et al. and Knockdown of Livin inhibits growth and invasion of gastric cancer cells through blockade of the MAPK pathway in vitro and in vivo by J.-M. OU et al. Subcutaneous models are highly practical because they allow researchers to directly measure tumor volume with calipers, track growth rates, and assess the balance between tumor suppression and systemic toxicity. In Integrating network pharmacology, molecular docking and experimental verification to reveal the mechanism of artesunate in inhibiting choroidal melanoma, Ke Lei utilizes this subcutaneous approach to validate a compound's therapeutic effect on tumor weight and growth.

However, ectopic environments (like the skin) lack the specific physiological signaling, vasculature, and extracellular matrix of the tumor's native organ. To capture these critical interactions, researchers deploy orthotopic models, implanting cancer cells directly into their organ of origin. For example, to study glioblastoma, Shaolu Zhang et al. in BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair implanted luciferase-expressing tumor cells directly into the brains of mice. By leveraging bioluminescence imaging, the authors could non-invasively track real-time tumor progression through the skull. Similarly, orthotopic models are essential for studying metastasis; Jisheng Hu et al. in MiR-361-3p regulates ERK1/2-induced EMT via DUSP2 mRNA degradation in pancreatic ductal adenocarcinoma utilized orthotopic liver models to evaluate how specific genetic modifications influence the systemic migration and secondary colonization of pancreatic cancer cells.

Preserving Patient Architecture via Patient-Derived Xenografts

While established commercial cell lines are convenient, they often lose their original cellular heterogeneity and architectural complexity after decades of adaptation to plastic dishes. Patient-Derived Xenograft (PDX) models solve this by taking fresh tumor tissue directly from a patient surgery and engrafting it into an immunodeficient mouse.

As Jun Lu et al. demonstrate in Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets, PDX models retain the specific genomic alterations and driver mutations of the original patient tumor. This high fidelity makes them indispensable tools for genome-guided precision oncology, allowing researchers to test targeted single-agent or combination therapies against authentic human tumor profiles in vivo before clinical deployment.

The Immunotherapy Frontier: Syngeneic and Humanized Systems

The very feature that makes traditional xenografts work—the absence of a host immune system—renders them useless for evaluating modern immunotherapies. To study how a drug interacts with both the tumor and the immune system, researchers use two main strategies: syngeneic modeling and humanized mice.

Syngeneic modeling involves transplanting mouse-derived tumor lines into immunocompetent mice of the same genetic background, a technique highlighted in Novel Paired Cell Lines for the Study of Lipid Metabolism and Cancer Stemness of Hepatocellular Carcinoma by Yun-Hsin Cheng et al. Because the host's immune system is fully intact, researchers can observe how genetic modifications or therapeutic agents alter immune cell recruitment and microenvironmental remodeling, as explored in LIMCH1 inhibits antitumor immunity by upregulating PDL1 in triple-negative breast cancer by Minghan Qiu et al.

Alternatively, to evaluate human-specific immune targets, researchers develop humanized mouse models. In RCAd-LTH-shPD-L1, a double-gene recombinant oncolytic adenovirus with enhanced antitumor immunity, increases lymphocyte infiltration and reshapes the tumor microenvironment, Yuan Meng et al. engrafted immunodeficient mice with human peripheral blood mononuclear cells (PBMCs), creating a chimeric system with functional human immune components. This allows for the preclinical evaluation of complex therapies by directly monitoring human T-cell infiltration and microenvironmental reshaping in a living host, a paradigm also utilized in An Fc-Competent Anti-Human TIGIT Blocking Antibody Ociperlimab (BGB-A1217) Elicits Strong Immune Responses and Potent Anti-Tumor Efficacy in Pre-Clinical Models by Xin Chen et al.

Key Foundational Work

Metastasis of a human pancreatic adenocarcinoma (RWP-1) in nude mice (1982) — contributed 2 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_in_vivo_xenograft_model_ded8f03d,
  title = {in vivo xenograft model},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/in-vivo-xenograft-model/rdr_ded8f03d826c4c8bbe69c8703abc6f95},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_in_vivo_xenograft_model_ded8f03d_v1,
  title = {in vivo xenograft model},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/in-vivo-xenograft-model/rdr_ded8f03d826c4c8bbe69c8703abc6f95/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake